至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing.

EMBO Mol Med. 2018; 
Hawksworth J,, Satchwell TJ,,, Meinders M, Daniels DE,, Regan F,, Thornton NM, Wilson MC, Dobbe JG, Streekstra GJ, Trakarnsanga K, Heesom KJ, Anstee DJ,,, Frayne J,, Toye AM,,.
Products/Services Used Details Operation
Custom Vector Construction Lentiviral transduction of single guide CRISPR–Cas9 vectors Pre-validated CRISPR guides to blood group genes in the lentiviral vector lentiCRISPRv2 were ordered from GenScript (Sanjana et al, 2014). Get A Quote

摘要

Regular blood transfusion is the cornerstone of care for patients with red blood cell (RBC) disorders such as thalassaemia or sickle-cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR-mediated genome editing of an immortalised human erythroblast cell line (BEL-A) to generate multiple enucleation competent cell lines deficient in individual blood groups. Edits are combined to generate a single cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull), Kell (K0), Duffy (Fynull), GPB (S-s-U-). These cells can be differentiated to gene... More

关键词

CRISPR ; BEL‐A; erythroid; transfusion; universal donor